Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 4.9 (10)
  • Courses
  • Updated Weekly

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. 1d ago

    Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

    In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including: CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistancePresenters: BJ Rimel, MDDivision Chief, Gynecologic OncologyProfessor, Department of OB/GYNUniversity of WashingtonClinical Director of Gynecologic OncologyFred Hutchinson Cancer CenterSeattle, Washington Elizabeth Lee, MDDivision of Gynecologic OncologyCenter for Cancer Therapeutic InnovationDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, Massachusetts Link to full program: https://bit.ly/3SqCAZ6 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing

  2. 1d ago

    ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer

    In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including: Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patientsResults from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interactionPresenters: Hope S. Rugo, MD, FASCODirector, Women’s Cancer ProgramDivision Chief, Breast Medical OncologyProfessor, Department of Medical Oncology & Therapeutics ResearchCity of Hope Comprehensive Cancer CenterProfessor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast OncologyUniversity of California, San FranciscoSan Francisco, California Nerea Lopetegui-Lia, MDAssistant ProfessorDivision of Medical Oncology, Breast SectionDepartment of Internal MedicineThe Ohio State UniversityColumbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer

  3. Aug 24

    CELMoDs on the Horizon: A New Chapter in Lymphoma Care

    Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include:  Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies Presenters: Alex F. Herrera, MD Chief, Division of Lymphoma Professor, Department of Hematology and Hematopoietic Cell Transplantation Director, Toni Stephenson Lymphoma Center City of Hope Duarte, California Marc Hoffmann, MD Director, Lymphoma Program Medical Director, Lean and Quality Improvement Associate Professor Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center Kansas City, Kansas Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to CME: Claim Credit Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    CELMoDs on the Horizon: A New Chapter in Lymphoma Care

  4. Aug 20

    Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma

    In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including: Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolment Presenters:Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research  Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program:https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing tothe Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma

  5. Aug 20

    Experts Discuss CELMoD Agents for Multiple Myeloma

    In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including:  The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settings Presenters:Meletios-Athanasios (Thanos) C. Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece María-Victoria Mateos, MD, PhD Myeloma Unit, Director Professor of Medicine University Hospital of Salamanca Salamanca, Spain Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program:https://bit.ly/4xgnHri Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Experts Discuss CELMoD Agents for Multiple Myeloma

  6. Aug 14

    Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer

    In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support PresentersDanielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program:https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer:https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC:https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer

  7. Aug 13

    TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care

    Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT.  Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care

  8. Aug 12

    Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

    In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program: https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
See All (268)

Ratings & Reviews

4.9
out of 5
10 Ratings

About

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Information

You Might Also Like